Table 2 Description of reactions
Total | Negative | Positive | |
|---|---|---|---|
Reaction to AB before referral to DC | 140 | 136 | 4 |
Once | 128 (91%) | 124 (91%) | 4 (100%) |
More than once | 12 (8.6%) | 12 (8.8%) | |
Time period from AB dose to symptoms | 135 | 131 | 4 |
< 1 day | 86 (64%) | 84 (64%) | 2 (50%) |
1–2 days | 27 (20%) | 25 (19%) | 2 (50%) |
> 2 days | 22 (16%) | 22 (17%) | |
Duration of symptoms | 137 | 133 | 4 |
< 1 day | 66 (48%) | 63 (47%) | 3 (75%) |
> 1 day | 60 (44%) | 59 (44%) | 1 (25%) |
Unknown | 11 (8.0%) | 11 (8.3%) | |
Medical treatment | 136 | 132 | 4 |
None | 105 (77%) | 103 (78%) | 2 (50%) |
Antihistamines | 30 (22%) | 28 (21%) | 2 (50%) |
Corticosteroids | 8 (5.8%) | 8 (6.1%) | |
Epinephrine | 1 (0.7%) | 1 (0.8%) | |
Bronchodilators | 2 (1.5%) | 2 (1.5%) | |
Indication of AB treatment | 133 | 129 | 4 |
Airway infection | 17 (13%) | 16 (12%) | 1 (25%) |
Tonsillitis | 21 (16%) | 21 (16%) | |
Sinusitis/otitis | 76 (57%) | 73 (57%) | 3 (75%) |
Other (impetigo, arthritis etc.) | 15 (11%) | 15 (12%) | |
Unknown | 4 (3.0%) | 4 (3.1%) |